Journal article

The molecular origin and taxonomy of mucinous ovarian carcinoma

Dane Cheasley, Matthew J Wakefield, Georgina L Ryland, Prue E Allan, Kathryn Alsop, Kaushalya C Amarasinghe, Sumitra Ananda, Michael S Anglesio, George Au-Yeung, Maret Bohm, David Dl Bowtell, Alison Brand, Georgia Chenevix-Trench, Michael Christie, Yoke-Eng Chiew, Michael Churchman, Anna DeFazio, Renee Demeo, Rhiannon Dudley, Nicole Fairweather Show all



Mucinous ovarian carcinoma (MOC) is a unique subtype of ovarian cancer with an uncertain etiology, including whether it genuinely arises at the ovary or is metastatic disease from other organs. In addition, the molecular drivers of invasive progression, high-grade and metastatic disease are poorly defined. We perform genetic analysis of MOC across all histological grades, including benign and borderline mucinous ovarian tumors, and compare these to tumors from other potential extra-ovarian sites of origin. Here we show that MOC is distinct from tumors from other sites and supports a progressive model of evolution from borderline precursors to high-grade invasive MOC. Key drivers of progressi..

View full abstract


Awarded by National Health and Medical Research Council of Australia (NHMRC)

Awarded by U.S. Army Medical Research and Materiel Command

Awarded by National Health and Medical Research Council

Awarded by Cancer Institute NSW

Awarded by National Institutes of Health


Funding Acknowledgements

This study was supported by the National Health and Medical Research Council of Australia (NHMRC) Grants #APP1045783 and #628434 and the Peter MacCallum Cancer Foundation. The authors acknowledge the Bioinformatics and Molecular Genomics Core Facilities of the Peter MacCallum Cancer Centre, which were supported by the Australian Cancer Research Foundation. We thank Sachintha Wijegunasekara and Ellen Gunn for technical assistance, and Margot Osinski (Royal Women's Hospital) for database assistance. The following cohorts were supported as follows: CASCADE: Supported by the Peter MacCallum Cancer Foundation. AOCS: The Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Council Tasmania and The Cancer Foundation of Western Australia (Multi-State Applications 191, 211 and 182) and the National Health and Medical Research Council of Australia (NHMRC; ID400413 and ID400281). The Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation. The AOCS also acknowledges the cooperation of the participating institutions in Australia and acknowledges the contribution of the study nurses, research assistants and all clinical and scientific collaborators to the study. The complete AOCS Study Group can be found at We would like to thank all of the women who participated in these research programs. COEUR: This study uses resources provided by the Canadian Ovarian Cancer Research Consortium's - COEUR biobank funded by the Terry Fox Research Institute and managed and supervised by the Centre hospitalier de l'Universite de Montreal (CRCHUM). The Consortium acknowledges contributions to its COEUR biobank from Institutions across Canada (for a full list see aspx). The Gynaecological Oncology Biobank at Westmead is a member of the Australasian Biospecimen Network-Oncology group, which was funded by the National Health and Medical Research Council Enabling Grants ID 310670 & ID 628903 and the Cancer Institute NSW Grants ID 12/RIG/1-17 & 15/RIG/1-16. OVCARE receives core funding from The BC Cancer Foundation and the VGH and UBC Hospital Foundation. Mayo Clinic: National Institutes of Health (R01-CA122443, P30-CA15083, P50CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation. Edinburgh: We extend our thanks to the Edinburgh Ovarian Cancer Database from which data were collected for this research and the Nicola Murray Foundation for supporting the Nicola Murray Centre for Ovarian Cancer Research.